Treatment of Cultured Sebocytes with an EGFR Inhibitor Does Not Lead to Significant Upregulation of Inflammatory Biomarkers
January 2011
in “
Annals of Dermatology
”
New to Epidermal Growth Factor? There is a guide in the encyclopedia. Read the guide → EGFR inhibitor cetuximab EGFR ligands EGF TGF-alpha inflammatory cytokines IL-1 IL-6 TNF-alpha PPAR-gamma EGFR sebocytes acneiform eruptions epidermal growth factor receptor inhibitor Erbitux epidermal growth factor transforming growth factor-alpha interleukin-1 interleukin-6 tumor necrosis factor-alpha peroxisome proliferator-activated receptor gamma
Studysummary This study found that EGFR inhibitors and ligands did not significantly affect the expression of inflammatory biomarkers in cultured sebocytes, except for a notable increase in IL-1 expression with EGF treatment.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
In a 2011 study by Lee et al., the impact of an EGFR inhibitor (cetuximab) and EGFR ligands (EGF and TGF-alpha) on inflammatory cytokine production in cultured sebocytes was examined. The study employed various methods to measure the expression of IL-1, IL-6, TNF-alpha, PPAR-gamma, and EGFR. Results indicated no significant upregulation of these inflammatory biomarkers when sebocytes were treated with either the EGFR inhibitor or the ligands, except for a notable increase in IL-1 expression in the EGF-treated group. The study concluded that EGFR inhibitors and ligands do not significantly provoke inflammatory biomarker expression in sebocytes, suggesting that further research is needed to understand the role of sebaceous glands in the acneiform eruptions caused by EGFR inhibitors.
